Read by QxMD icon Read

Future Oncology

Sandra Assoun, Solenn Brosseau, Christelle Steinmetz, Valérie Gounant, Gérard Zalcman
Despite recent advances in metastatic lung cancer treatment with the advent of immune checkpoint inhibitors and molecules targeting addictive genomic abnormalities, prognosis of most of the patients remains unfavorable. Combination approaches with older drugs, such as bevacizumab, should be thus envisioned. Bevacizumab is a monoclonal anti-VEGF antibody, approved by the US FDA and the EMA in first-line and maintenance settings of advanced nonsquamous non-small-cell lung cancer (NSCLC) treatment, in association with platinum-based chemotherapy...
August 16, 2017: Future Oncology
Uwe Reinhold
BF-200 ALA is a combination of a nanoscale-lipid vesicle formulation and the prodrug 5-aminolevulinic acid (5-ALA). The nanoemulsion stabilizes the prodrug and enhances its penetration through the stratum corneum. It has shown excellent therapeutic results in both lesion and field-directed photodynamic therapy of actinic keratosis (AK). AK is an early form of epidermal neoplasia and a precursor of invasive cutaneous squamous cell carcinoma. It is characterized by the combination of visible neoplastic lesions and surrounding tissue also harboring tumorigenic UV-induced mutations: a concept called field cancerization...
August 14, 2017: Future Oncology
Julia J Scarisbrick
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Response rates >75% with manageable adverse effects in refractory Hodgkin lymphoma and systemic anaplastic large-cell lymphoma led to accelerated approval for both. Phase II studies in CD30-expressing CTCL followed and showed similar efficacy, which was ratified in a Phase III trial of BV versus physician's choice (methotrexate or bexarotene) showing significant improved responses without increase in severe adverse effects although peripheral neuropathy is frequent...
August 14, 2017: Future Oncology
Tomas Garzon-Muvdi, Carmen Kut, Xingde Li, Kaisorn L Chaichana
Gliomas are CNS neoplasms that infiltrate the surrounding brain parenchyma, complicating their treatment. Tools that increase extent of resection while preventing neurological deficit are essential to improve prognosis of patients diagnosed with gliomas. Tools such as intraoperative MRI, ultrasound and fluorescence-guided microsurgery have been used in the surgical resection of CNS gliomas with the goal of maximizing extent of resection to improve patient outcomes. In addition, emerging experimental techniques, for example, optical coherence tomography and Raman spectroscopy are promising techniques which could 1 day add to the increasing armamentarium used in the surgical resection of CNS gliomas...
August 10, 2017: Future Oncology
David Atallah, Elie El Rassy, Georges Chahine
No abstract text is available yet for this article.
August 9, 2017: Future Oncology
Yolanda Escobar Alvarez, Claudia Agamez Insignares, Monica Ahumada Olea, Olga Barajas, German Calderillo, Jenny Cecilia Calvache Guamán, Ricardo Caponero, Benjamín A Cavenago Salazar, Auro Del Giglio, Ana Rocío Pupo Araya, Ricardo Villalobos-Valencia, Andrés Yepes Pérez, Nilda Zumelzu Delgado
Generating a consensus in the Latin-American region on cancer pain management is a current need. Thus a panel of Latin-American experts met in Madrid in March 2017 in order to review the published literature, discuss the best approach for cancer pain classification and evaluation and also make recommendations of pharmacological and nonpharmacological therapies for cancer pain management improvement in Latin-American countries. The result of that meeting is presented in this document. The experts participating were from Costa Rica, Mexico, Chile, Colombia, Peru, Brazil and Ecuador, and the project coordinator was from Spain...
August 4, 2017: Future Oncology
Shilpa Paul, Caitlin R Rausch, Hagop Kantarjian, Elias J Jabbour
Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL. However, the high cure rates seen in pediatric ALL have not been replicated in adults. In recent years, the development of monoclonal antibodies targeting cell surface antigens, such as CD19 and CD20, have significantly improved outcomes when used alone or in combination with cytotoxic chemotherapy. With these novel agents come challenges in managing adverse events, understanding mechanisms of resistance and determining their optimal place in therapy alongside conventional chemotherapy and allogeneic stem cell transplant...
August 4, 2017: Future Oncology
Junya Ohtake, Tetsuro Sasada
No abstract text is available yet for this article.
August 4, 2017: Future Oncology
Meghan J Mooradian, Ryan J Sullivan
Recent advances in the use of immunotherapy have led to historic advancements in the field of oncology. Checkpoint inhibitors have demonstrated significant effectiveness against a broadening range of cancers. However, despite the success of antibodies against the immune regulators, CTLA4 and PD-L1/PD-1, only a subset of patients will have a durable response to these therapies, which implies that a broader view of cancer immunity is required. It is becoming increasingly apparent that combination therapy to target multiple events in the cancer-immunity cycle is needed and could potentially extend the benefit of immunotherapy to a larger population...
August 4, 2017: Future Oncology
Iulia Andras, Nicolae Crisan, Stefan Vesa, Razvan Rahota, Florina Romanciuc, Andrei Lazar, Carmen Socaciu, Deliu-Victor Matei, Ottavio de Cobelli, Ioan-Stelian Bocsan, Radu-Tudor Coman
AIM: To assess the predictive value of metabolomic analysis for the presence of prostate cancer (PCa) at first systematic biopsy. PATIENTS & METHODS: Ninety serum samples from patients with suspicion for PCa were included. Targeted and nontargeted metabolomic analysis was performed. RESULTS: Six metabolites were combined into a predictive score. A cutoff value of 0.528 for the metabolomic score showed a good accuracy for the prediction of PCa at biopsy (Area under the curve (AUC): 0...
August 4, 2017: Future Oncology
Alberto Fusi, Angus Dalgleish
Immune checkpoint blockades have recently emerged as a breakthrough treatment for solid tumors showing high response rates and long durability. In melanoma, the combination of ipilimumab with nivolumab showed high efficacy. However, still half the patients do not respond to this treatment. In order to increase the therapeutic ratio in melanoma and other cancers, different approaches are under evaluation. Three relevant questions are at the moment driving the research community: how to maximize benefit while minimizing toxicity; how to better identify patients who are more likely to benefit from immunotherapy; how to convert nonresponders into responders...
August 4, 2017: Future Oncology
William Grubb, Rebekah Young, Jimmy Efird, Charulata Jindal, Tithi Biswas
Owing to its aggressive course, triple-negative breast cancer remains an important clinical issue of current interest compared with hormone-receptor positive subtypes. Recent research has focused on determining the optimal local therapy (breast conversation therapy vs mastectomy) for this cancer subtype. In this overview, we examine outcomes based on immunohistochemistry, gene expression profiles, type of local therapy and in the era of neoadjuvant chemotherapy. Based on multiple observational reports risk for locoregional recurrence appears to be similar to reported outcomes in other subtypes...
August 4, 2017: Future Oncology
Nicolas Boisgerault, Marc Grégoire, Jean-François Fonteneau
No abstract text is available yet for this article.
August 4, 2017: Future Oncology
Raheleh Roudi, Marzieh Ebrahimi, Ahmad Shariftabrizi, Zahra Madjd
Treatment modalities can reduce cancer-related mortality; however, a majority of patients develop drug resistance, metastasis and relapse. It has been proposed that tumorigenic characteristics of tumors are related to a proportion of cancer cells, termed cancer stem cells (CSCs). Following the first evidence regarding the existence of CSC population in acute myeloid leukemia in 1997, publications in CSCs field showed an explosive trend in all cancer types around the world. First research paper in the field of CSCs in Iran was published in 2004 on prostate cancer...
August 4, 2017: Future Oncology
Daphne W Dumoulin, Joachim Gjv Aerts, Robin Cornelissen
No abstract text is available yet for this article.
August 4, 2017: Future Oncology
Jie Wu, Ai Guo, Qiang Li, Difan Wang
AIM: The prognostic role of p53 protein expression in osteosarcoma has been reported, but the results remain conflicting. MATERIALS & METHODS: The relevant literature databases were searched to get eligible articles published in English. The overall ORs or HRs and their corresponding 95% CIs were calculated. RESULTS: The results indicated that p53 protein expression was not linked to age factor, gender, tumor grade, cancer metastasis and response to chemotherapy...
August 2, 2017: Future Oncology
Kiruthikah Thillai, Krishnie Srikandarajah, Paul Ross
Hepatocellular carcinoma is one of the fastest growing causes of cancer-related mortality worldwide. Sorafenib was the first and only drug to improve survival for patients with advanced disease, and has been the cornerstone of treatment for nearly a decade. Regorafenib is a multikinase inhibitor that has recently been shown to significantly improve survival in patients who have progressed on first-line sorafenib. In this review, we discuss the pharmacokinetic and pharmacodynamics properties of regorafenib and its efficacy and tolerability in patients with advanced hepatocellular carcinoma...
August 2, 2017: Future Oncology
Niranjan J Sathianathen, Nicolas Geurts, Rajesh Nair, Nathan Lawrentschuk, Declan G Murphy, Alastair D Lamb
PSMA-PET is changing how we stage prostate cancer, both in the primary setting and with relapse after treatment. It allows us to identify lesions in the bones and lymph nodes that were not previously visible on conventional imaging with bone scan and CT/MRI. In this Special Report we review the 'state of the art' for PSMA imaging and discuss the implications for treatment decisions in prostate cancer. We liken early high risk or metastatic prostate to a common phytological problem: the dandelion. In this analogous situation, we consider the additional evidence needed for us to start plucking out the original dandelion and for us to focus attention on killing the seeded weeds that are identifiable elsewhere in the lawn...
August 1, 2017: Future Oncology
Constantinos Giaginis, Nikolaos Tsoukalas, Paraskevi Alexandrou, Gerasimos Tsourouflis, Eugene Dana, Ioanna Delladetsima, Efstratios Patsouris, Stamatios Theocharis
AIM: To evaluate the clinical significance of farnesoid X receptor (FXR) in thyroid neoplasia. PATIENTS & METHODS: FXR expression was assessed immunohistochemically on 88 thyroid neoplastic tissues (benign = 44, malignant = 44). RESULTS: Enhanced FXR was more frequently observed in papillary carcinomas compared with hyperplastic nodules (p = 0.0489). In malignant lesions, elevated FXR was associated with capsular (p = 0.0004) and vascular invasion (p = 0...
August 1, 2017: Future Oncology
A R Alitto, R Gatta, Bgl Vanneste, M Vallati, E Meldolesi, A Damiani, V Lanzotti, G C Mattiucci, V Frascino, C Masciocchi, F Catucci, A Dekker, P Lambin, V Valentini, G Mantini
AIM: Identifying the best care for a patient can be extremely challenging. To support the creation of multifactorial Decision Support Systems (DSSs), we propose an Umbrella Protocol, focusing on prostate cancer. MATERIALS & METHODS: The PRODIGE project consisted of a workflow for standardizing data, and procedures, to create a consistent dataset useful to elaborate DSSs. Techniques from classical statistics and machine learning will be adopted. The general protocol accepted by our Ethical Committee can be downloaded from cancerdata...
July 31, 2017: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"